department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

TERIPARATIDE · pharmadog

pharmadog
drugs
TERIPARATIDE

drug · protein

patient view →

EB-613

Marketedupdated 2mo ago

by $ENTXW Entera Bio Ltd.🔗 ChEMBL

Approved

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 8 investigational indications.

targets

Parathyroid hormone/parathyroid hormone-related peptide receptor

all catalysts(1)

approval · 1

News(0)

no news has mentioned this drug yet

brand

TERIPARATIDE

trade names

Bonsity, Forsteo, Forteo, Kauliv, Livogiva, Movymia

generic

teriparatide

MOA

Parathyroid hormone receptor agonist

indication

Osteoporosis

phase

marketed

TERIPARATIDE — FDA approval

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 42m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$AMPH19.39-1.25%

🐶 often sniffed alongside

top 2

tagApproval2 co-mentions · 1 sources
drugTERIPARATIDE1 co-mentions · 1 sources

Trials studying EB-613

phase3A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidismrecruitingn=36
—A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)recruitingn=10
—A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeedingrecruitingn=50
—Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidismapproved for marketing
phase3To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracturenot yet recruitingn=282
—Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Womencompletedn=22,054
phase3Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fracturescompletedn=34